Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Raymond

Showing results (71-80 of 173) with videos related to

Pageof 18
Sort By:
Targeted Oncology|December 22, 2023
Ezurpimtrostat, A Palmitoyl-Protein Thioesterase-1 Inhibitor, Combined with PD-1 Inhibition Provides CD8<sup>+</sup> Lymphocyte Repopulation in Hepatocellular CarcinomaEloïne Bestion, Madani Rachid, Annemilaï Tijeras-Raballand, et al.
International Journal of Nanomedicine|December 7, 2016
Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I studyRomain Coriat, Sandrine J Faivre, Olivier Mir, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 2008
Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignanciesSandrine Faivre, Catherine Delbaldo, Valérie Boige, et al.
Investigational New Drugs|June 10, 2006
Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with topotecan in patients with advanced malignanciesHervé Ghesquières, Sandrine Faivre, Latifa Djafari, et al.
Molecular Diagnosis & Therapy|January 24, 2024
Unraveling Emerging Anal Cancer Clinical Biomarkers from Current Immuno-Oncogenomics AdvancesSoledad Iseas, Golubicki Mariano, Louis Gros, et al.
Targeted Oncology|May 16, 2012
Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinibSandrine Faivre, Maxime Ronot, Chantal Dreyer, et al.
Cancer Chemotherapy and Pharmacology|March 13, 2013
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenibMaria Serova, Armand de Gramont, Annemilaï Tijeras-Raballand, et al.
Endocrine-Related Cancer|June 24, 2010
Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumorsDermot O'Toole, Anne Couvelard, Vinciane Rebours, et al.
American Journal of Clinical Oncology|August 19, 2009
Reports of clinical benefit of plitidepsin (Aplidine), a new marine-derived anticancer agent, in patients with advanced medullary thyroid carcinomaChristophe Le Tourneau, Sandrine Faivre, Eva Ciruelos, et al.
European Journal of Cancer (Oxford, England : 1990)|June 16, 2004
Locoregional effects of pegylated liposomal doxorubicin (Caelyx) in irradiated area: a phase I-II study in patients with recurrent squamous cell carcinoma of the head and neckSandrine Faivre, Hassan Alsabe, Latifa Djafari, et al.
Pageof 18

Showing results (71-80 of 173) with videos related to

Sort By:
Pageof 18
Targeted Oncology|December 22, 2023
Ezurpimtrostat, A Palmitoyl-Protein Thioesterase-1 Inhibitor, Combined with PD-1 Inhibition Provides CD8<sup>+</sup> Lymphocyte Repopulation in Hepatocellular CarcinomaEloïne Bestion, Madani Rachid, Annemilaï Tijeras-Raballand, et al.
International Journal of Nanomedicine|December 7, 2016
Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I studyRomain Coriat, Sandrine J Faivre, Olivier Mir, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 2008
Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignanciesSandrine Faivre, Catherine Delbaldo, Valérie Boige, et al.
Investigational New Drugs|June 10, 2006
Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with topotecan in patients with advanced malignanciesHervé Ghesquières, Sandrine Faivre, Latifa Djafari, et al.
Molecular Diagnosis & Therapy|January 24, 2024
Unraveling Emerging Anal Cancer Clinical Biomarkers from Current Immuno-Oncogenomics AdvancesSoledad Iseas, Golubicki Mariano, Louis Gros, et al.
Targeted Oncology|May 16, 2012
Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinibSandrine Faivre, Maxime Ronot, Chantal Dreyer, et al.
Cancer Chemotherapy and Pharmacology|March 13, 2013
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenibMaria Serova, Armand de Gramont, Annemilaï Tijeras-Raballand, et al.
Endocrine-Related Cancer|June 24, 2010
Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumorsDermot O'Toole, Anne Couvelard, Vinciane Rebours, et al.
American Journal of Clinical Oncology|August 19, 2009
Reports of clinical benefit of plitidepsin (Aplidine), a new marine-derived anticancer agent, in patients with advanced medullary thyroid carcinomaChristophe Le Tourneau, Sandrine Faivre, Eva Ciruelos, et al.
European Journal of Cancer (Oxford, England : 1990)|June 16, 2004
Locoregional effects of pegylated liposomal doxorubicin (Caelyx) in irradiated area: a phase I-II study in patients with recurrent squamous cell carcinoma of the head and neckSandrine Faivre, Hassan Alsabe, Latifa Djafari, et al.
Pageof 18